Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1841 Target Snapshot

Tyrosine-protein kinase Fyn · SINGLE PROTEIN · Homo sapiens

4,331Compounds
636Assays
65Approved Drugs
5,230.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Tyrosine-protein kinase Fyn shows clinical signal disease relevance led by cancer. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P06241. Start with cancer, then reuse UniProt P06241 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P06241 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cancer

Tyrosine-protein kinase Fyn shows clinical signal disease relevance led by cancer. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries clinical signal support. Linked drugs include JNJ-26483327. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Fyn as ChEMBL target CHEMBL1841, mapped to UniProt P06241. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase Fyn
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1841
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P06241
Tyrosine-protein kinase Fyn
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase Fyn is the right protein anchor across sources, using UniProt P06241 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase Fyn
UniProt AccessionP06241
Component TypeProtein
Sequence Length537 aa

Tyrosine-protein kinase Fyn

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase Fyn, mapped to UniProt P06241. Sequence length is 537 aa.

Mapped IDP06241
Review nameTyrosine-protein kinase Fyn
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Tyrosine-protein kinase Fyn shows clinical signal disease relevance led by cancer.

Clinical signal Phase I
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugJNJ-26483327
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with cancer because it currently carries clinical signal support. Linked drugs include JNJ-26483327. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

65
Approved
14
Phase III
34
Phase II
17
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC502,691.0
KI1,738.0
EC50400.0
KD401.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5416410 9.7 IC50 0.2 Approved
CHEMBL45177 9.52 IC50 0.3 Preclinical
CHEMBL1969102 9.5 Ki 0.3162 Preclinical
CHEMBL1171837 9.44 IC50 0.36 Approved
CHEMBL1994938 9.4 Ki 0.3981 Preclinical
CHEMBL249097 9.4 Kd 0.4 Preclinical
CHEMBL1982476 9.2 Ki 0.631 Preclinical
CHEMBL5416410 9.1 Kd 0.79 Approved
CHEMBL364623 9.0 IC50 1.0 Preclinical
CHEMBL515414 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

407
5.0
616
5.5
491
6.0
204
6.5
109
7.0
45
7.5
46
8.0
20
8.5
12
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
ENTRECTINIB
CHEMBL1983268
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
DABRAFENIB
CHEMBL2028663
Approved 2013
IBRUTINIB
CHEMBL1873475
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
EBASTINE
CHEMBL305660
Approved 1990
AMIODARONE
CHEMBL633
Approved 1985
TANNIC ACID
CHEMBL506247
Approved 1982
ACETIC ACID
CHEMBL539
Approved 1982
SULOCTIDIL
CHEMBL404849
Approved 1979
Assay Landscape

Assay Landscape

636
Total Assays
1,015
Tested Compounds
3
Assay Types
Binding — 621 assays, 1,015 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 465 893 5.9
cell-based format 66 73 5.5
assay format 63 21 6.6
subcellular format 26 28 6.6
tissue-based format 1 0
Functional — 8 assays, 241 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 237 6.5
cell-based format 3 4 5.8
ADME — 7 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 4 1 6.8
assay format 1 0
cell-based format 1 0
tissue-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine